In:
Otolaryngology–Head and Neck Surgery, Wiley, Vol. 127, No. 3 ( 2002-09), p. 182-189
Abstract:
We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis. STUDY DESIGN TeqCES was an open‐label, multicenter, noncomparative study of the safety and efficacy of gatifloxacin. More than 11,000 adult patients with acute uncomplicated rhinosinusitis received gatifloxacin 400 mg once daily for 10 days. RESULTS Moraxella catarrhalis (91% β‐lactamase producers), Haemophilus influenzae (28% β‐lactamase producers), Streptococcus pneumoniae (18% intermediately resistant and 14% fully resistant to penicillin), and Staphylococcus aureus were the predominant pathogens isolated from purulent nasal discharge. More than 99% of rhinosinusitis pathogens isolated from the nasopharynx of patients meeting the clinical criteria for rhinosinusitis were susceptible to gatifloxacin. Among 10,353 patients whose clinical response could be determined, 91.6% were cured. Clinical cure rates exceeded 90% for the major pathogens. Gatifloxacin was well tolerated; drug‐related adverse events that occurred in 1% or more of patients were nausea (4.4%), dizziness (1.8%), diarrhea (1.4%), and headache (1.0%). CONCLUSION Gatifloxacin is effective for patients with acute bacterial rhinosinusitis in the community.!
Type of Medium:
Online Resource
ISSN:
0194-5998
,
1097-6817
DOI:
10.1067/mhn.2002.127590
Language:
English
Publisher:
Wiley
Publication Date:
2002
detail.hit.zdb_id:
2008453-5
Permalink